298 related articles for article (PubMed ID: 28770459)
1. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.
Nielsen R; Jorsal A; Iversen P; Tolbod LP; Bouchelouche K; Sørensen J; Harms HJ; Flyvbjerg A; Tarnow L; Kistorp C; Gustafsson I; Bøtker HE; Wiggers H
J Nucl Cardiol; 2019 Apr; 26(2):585-597. PubMed ID: 28770459
[TBL] [Abstract][Full Text] [Related]
2. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism.
Nielsen R; Jorsal A; Iversen P; Tolbod L; Bouchelouche K; Sørensen J; Harms HJ; Flyvbjerg A; Bøtker HE; Wiggers H
J Nucl Cardiol; 2018 Feb; 25(1):169-176. PubMed ID: 27473218
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Leccisotti L; Cinti F; Sorice GP; D'Amario D; Lorusso M; Guzzardi MA; Mezza T; Gugliandolo S; Cocchi C; Capece U; Indovina L; Ferraro PM; Iozzo P; Crea F; Giordano A; Giaccari A
Cardiovasc Diabetol; 2022 Sep; 21(1):173. PubMed ID: 36057768
[TBL] [Abstract][Full Text] [Related]
4. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Jorsal A; Kistorp C; Holmager P; Tougaard RS; Nielsen R; Hänselmann A; Nilsson B; Møller JE; Hjort J; Rasmussen J; Boesgaard TW; Schou M; Videbaek L; Gustafsson I; Flyvbjerg A; Wiggers H; Tarnow L
Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
[TBL] [Abstract][Full Text] [Related]
5. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
6. Low myocardial glucose uptake in Turner syndrome is unaffected by growth hormone: a randomized, placebo-controlled FDG-PET study.
Trolle C; Hjerrild B; Mortensen KH; Knorr S; Søndergaard HM; Christiansen JS; Gravholt CH
Clin Endocrinol (Oxf); 2015 Jul; 83(1):133-40. PubMed ID: 25645325
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.
Naoumova RP; Kindler H; Leccisotti L; Mongillo M; Khan MT; Neuwirth C; Seed M; Holvoet P; Betteridge J; Camici PG
J Am Coll Cardiol; 2007 Nov; 50(21):2051-8. PubMed ID: 18021872
[TBL] [Abstract][Full Text] [Related]
8. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).
Jorsal A; Wiggers H; Holmager P; Nilsson B; Nielsen R; Boesgaard TW; Kumme A; Møller JE; Videbæk L; Kistorp C; Gustafsson I; Tarnow L; Flyvbjerg A
BMJ Open; 2014 May; 4(5):e004885. PubMed ID: 24844271
[TBL] [Abstract][Full Text] [Related]
9. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.
Gejl M; Søndergaard HM; Stecher C; Bibby BM; Møller N; Bøtker HE; Hansen SB; Gjedde A; Rungby J; Brock B
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1165-9. PubMed ID: 22544917
[TBL] [Abstract][Full Text] [Related]
10. Insulin-stimulated myocardial glucose uptake and the relation to perfusion and the nitric oxide system.
Søndergaard HM; Bøttcher M; Schmitz O; Nielsen TT; Bøtker HE
J Vasc Res; 2004; 41(1):38-45. PubMed ID: 14726631
[TBL] [Abstract][Full Text] [Related]
11. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
[TBL] [Abstract][Full Text] [Related]
12. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
Kumarathurai P; Anholm C; Nielsen OW; Kristiansen OP; Mølvig J; Madsbad S; Haugaard SB; Sajadieh A
Cardiovasc Diabetol; 2016 Jul; 15(1):105. PubMed ID: 27455835
[TBL] [Abstract][Full Text] [Related]
13. Impaired myocardial perfusion is associated with increasing end-systolic- and end-diastolic volumes in patients with non-ischemic systolic heart failure: a cross-sectional study using Rubidium-82 PET/CT.
Byrne C; Hasbak P; Kjaer A; Thune JJ; Køber L
BMC Cardiovasc Disord; 2019 Mar; 19(1):68. PubMed ID: 30902043
[TBL] [Abstract][Full Text] [Related]
14. Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.
Mather KJ; Considine RV; Hamilton L; Patel NA; Mathias C; Territo W; Goodwill AG; Tune JD; Green MA; Hutchins GD
J Clin Endocrinol Metab; 2018 Sep; 103(9):3456-3465. PubMed ID: 30020461
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.
Hamad F; Elnour AA; Elamin A; Mohamed S; Yousif I; Don J; Abdi S; Al Amoodi A; Fathelrahman AI; Gnana K; Alanzi F; Abubakar AB; Magboul SM; Ahmed SA; Sadeq A
Curr Diabetes Rev; 2021; 17(3):280-292. PubMed ID: 32867644
[TBL] [Abstract][Full Text] [Related]
16. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
Redouane B; Greene SJ; Fudim M; Vaduganathan M; Ambrosy AP; Sun JL; DeVore AD; McNulty SE; Mentz RJ; Hernandez AF; Felker GM; Cooper LB; Borlaug BA; Velazquez EJ; Margulies KB; Sharma A
Circ Heart Fail; 2020 May; 13(5):e006758. PubMed ID: 32362166
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.
Lauritsen KM; Nielsen BRR; Tolbod LP; Johannsen M; Hansen J; Hansen TK; Wiggers H; Møller N; Gormsen LC; Søndergaard E
Diabetes; 2021 Mar; 70(3):800-808. PubMed ID: 33334875
[TBL] [Abstract][Full Text] [Related]
18. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
Kumarathurai P; Sajadieh A; Anholm C; Kristiansen OP; Haugaard SB; Nielsen OW
Cardiovasc Diabetol; 2021 Jan; 20(1):12. PubMed ID: 33413428
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
20. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
